Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ('ecstasy')-induced dopamine release and free radical formation in the mouse striatum.
The present study examined the mechanisms by which 3,4-methylenedioxymethamphetamine (MDMA) produces long-term neurotoxicity of striatal dopamine neurones in mice and the protective action of the dopamine uptake inhibitor GBR 12909. MDMA (30 mg/kg, i.p.), given three times at 3-h intervals, produced a rapid increase in striatal dopamine release measured by in vivo microdialysis (maximum increase to 380 +/- 64% of baseline). This increase was enhanced to 576 +/- 109% of baseline by GBR 12909 (10 mg/kg, i.p.) administered 30 min before each dose of MDMA, supporting the contention that MDMA enters the terminal by diffusion and not via the dopamine uptake site. This, in addition to the fact that perfusion of the probe with a low Ca(2+) medium inhibited the MDMA-induced increase in extracellular dopamine, indicates that the neurotransmitter may be released by a Ca(2+) -dependent mechanism not related to the dopamine transporter. MDMA (30 mg/kg x 3) increased the formation of 2,3-dihydroxybenzoic acid (2,3-DHBA) from salicylic acid perfused through a probe implanted in the striatum, indicating that MDMA increased free radical formation. GBR 12909 pre-treatment attenuated the MDMA-induced increase in 2,3-DHBA formation by approximately 50%, but had no significant intrinsic radical trapping activity. MDMA administration increased lipid peroxidation in striatal synaptosomes, an effect reduced by approximately 60% by GBR 12909 pre-treatment. GBR 12909 did not modify the MDMA-induced changes in body temperature. These data suggest that MDMA-induced toxicity of dopamine neurones in mice results from free radical formation which in turn induces an oxidative stress process. The data also indicate that the free radical formation is probably not associated with the MDMA-induced dopamine release and that MDMA does not induce dopamine release via an action at the dopamine transporter.
Camarero
Jorge
J
Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
Sanchez
Veronica
V
O'Shea
Esther
E
Green
A Richard
AR
Colado
M Isabel
MI
D000818:Animals; D001205:Ascorbic Acid / Q000737:chemistry; D001831:Body Temperature / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D003342:Corpus Striatum / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000032:analysis / Q000378:metabolism*; D018765:Dopamine Uptake Inhibitors / Q000032:analysis / Q000494:pharmacology*; D005296:Ferrous Compounds / Q000737:chemistry; D005609:Free Radicals / Q000378:metabolism; D062385:Hydroxybenzoates / Q000032:analysis / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D051379:Mice; D017551:Microdialysis; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology*; D010879:Piperazines / Q000032:analysis / Q000494:pharmacology*; D051381:Rats; D020156:Salicylic Acid / Q000378:metabolism; D013574:Synaptosomes / Q000737:chemistry; D013997:Time Factors
D018765:Dopamine Uptake Inhibitors; D005296:Ferrous Compounds; D005609:Free Radicals; D062385:Hydroxybenzoates; D010879:Piperazines; C009135:2,3-dihydroxybenzoic acid; C043425:vanoxerine; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D020156:Salicylic Acid; D001205:Ascorbic Acid; C029451:ferrous chloride; D002118:Calcium; D004298:Dopamine